Welcome to our dedicated page for Lemaitre Vasculr SEC filings (Ticker: LMAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for LeMaitre Vascular, Inc. (NASDAQ: LMAT), a Delaware-incorporated medical device company focused on vascular devices, implants, and services for peripheral vascular disease. Through these filings, investors can review the company’s formal disclosures on operations, financial condition, risk factors, and governance.
LeMaitre’s SEC submissions include annual reports on Form 10-K and quarterly reports on Form 10-Q, which present detailed financial statements, segment information, and discussions of risks such as competition, supplier dependence, regulatory compliance for devices and tissue products, international operations, product defects or recalls, litigation, and intellectual property protection. Current reports on Form 8-K, such as those referenced in the provided materials, disclose events like quarterly financial results, board decisions, and other material developments.
The company also uses its filings to describe capital markets activities, including the listing of its common stock on The Nasdaq Global Market under the symbol LMAT, the existence of convertible senior notes, dividend declarations, and share repurchase authorizations. These documents complement the non-GAAP metrics discussed in press releases by providing reconciliations and additional context for measures such as organic sales growth, adjusted margins, and EBITDA.
On Stock Titan, LeMaitre’s filings are updated in near real time from the SEC’s EDGAR system. AI-powered summaries help explain the key points in lengthy documents like 10-Ks and 10-Qs, highlight important changes from prior periods, and clarify the implications of 8-K disclosures. Users can also review insider-related filings such as Forms 3, 4, and 5, where available, to track transactions by directors and officers. This combination of raw filings and AI-generated insights allows readers to understand LMAT’s regulatory record and financial reporting more efficiently.
LeMaitre Vascular (LMAT) reported Q3 2025 results showing higher sales and earnings. Net sales were $61,046 thousand, up from $54,819 thousand a year ago. Net income rose to $17,362 thousand, and diluted EPS was $0.75 versus $0.49. Gross profit increased to $45,955 thousand as cost of sales declined to $15,091 thousand.
Results included a one‑time Employee Retention Credit benefit recorded in Q3: $4.8 million recognized as reductions to cost of sales ($2.7 million), sales and marketing ($0.8 million), general and administrative ($0.3 million), and research and development ($0.3 million), plus $0.7 million of interest income, and $0.7 million of related professional fees in general and administrative expense. The company did not recognize credits for claims filed for July–September 2021 under the One Big Beautiful Bill Act.
Year‑to‑date operating cash flow was $58,094 thousand. The balance sheet showed cash and cash equivalents of $25,494 thousand and short‑term marketable securities of $317,561 thousand. Convertible senior notes outstanding totaled $172,500 thousand; the conversion rate was adjusted to 8.3637 per $1,000 after a $0.20 per‑share dividend, which continued in Q4.
LeMaitre Vascular, Inc. filed an amendment to its prior report to disclose its Board of Directors’ decision on how often shareholders will vote on executive pay. At the 2025 annual meeting, stockholders indicated a preference for holding the non-binding advisory Say-on-Pay vote every year.
After considering this stockholder vote, the Board determined that LeMaitre Vascular will conduct future Say-on-Pay votes on an annual basis. No other changes were made to the original report of the 2025 Annual Meeting voting results.
LeMaitre Vascular furnished a press release detailing its preliminary financial and operational results for the quarter ended September 30, 2025. The disclosure is provided under Item 2.02 and is not deemed “filed” for Section 18 purposes, nor incorporated by reference except as expressly set forth.
The report includes Exhibit 99.1 (press release) and Exhibit 104 (Inline XBRL cover page data) and contains a forward-looking statements disclaimer.
LeMaitre Vascular, Inc. (LMAT) insider transaction by Chairman and CEO George W. LeMaitre. The Form 4 reports transactions dated 09/05/2025 showing multiple non-derivative dispositions and one indirect acquisition into an irrevocable life insurance trust. Aggregate reported sales: 42,500 shares disposed (three entries: 10,600; 10,600; 21,300) at $0 reported price under code "G," and a separate entry showing 21,300 shares acquired indirectly into the "LEMAITRE IRREVOCABLE LIFE INSURANCE TRUST OF 2025." Following the reported sales, direct beneficial ownership counts are reduced to 1,663,303; 1,684,603; and 1,695,203 on respective lines, while the trust holds 21,300 shares indirectly. The filer disclaims beneficial ownership of the trust shares except to the extent of any pecuniary interest.
LeMaitre Vascular (LMAT) Form 4: Director Martha Shadan reported acquisitions of dividend equivalent rights on 09/04/2025 that accrued on prior equity awards. The filing lists five separate accrual entries tied to restricted stock units and performance share units granted on 12/12/2022, 12/8/2023 and 12/6/2024. Each entry shows fractional amounts of economic share equivalents acquired (0.4173; 0.4173; 0.7138; 0.8546; 0.8697) at a reported price of $0, with ownership reported as Direct (D). The Form is signed by Nathan Ulrich on 09/08/2025.
LeMaitre Vascular director John A. Roush received multiple dividend equivalent rights tied to prior equity awards that vest proportionately with those awards. The Form 4 reports acquisitions on 09/04/2025 of dividend equivalent rights that are the economic equivalent of common stock: 0.4173, 0.4173, 0.7138, 0.8546 and 0.8697 shares, each recorded as acquired at $0 price and held directly. Each set of rights accrued on RSU or PSU awards granted in 2022, 2023 and 2024 and will vest in line with those underlying awards, converting economically into common stock when vested.
LeMaitre Vascular, Inc. (LMAT) director Bridget A. Ross reported the acquisition of dividend equivalent rights tied to prior equity awards. On 09/04/2025 Ms. Ross was credited with five separate accruals of dividend equivalent rights that are the economic equivalent of common shares. The accruals total individual amounts of 0.4173, 0.4173, 0.7138, 0.8546, and 0.8697 units and are linked to restricted stock unit and performance share unit awards granted on 12/12/2022, 12/08/2023, and 12/06/2024. Each accrual vests proportionately with the underlying award and carries a reported price of $0 per right. The Form 4 was signed on 09/08/2025.
LeMaitre Vascular director John James O'Connor reported changes in beneficial ownership on Form 4 relating to dividend equivalent rights that accrued on previously granted equity awards. The filing shows transactions dated 09/04/2025 recording a series of small accruals of dividend equivalent rights tied to restricted stock units and performance share unit awards granted on 12/12/2022, 12/8/2023 and 12/6/2024. Each dividend equivalent right is described as the economic equivalent of one share of the issuer's common stock. The filing was signed by Nathan Ulrich on 09/08/2025. The report indicates the form was filed by one reporting person who is a director of the issuer (LMAT).
Lawrence J. Jasinski, a director of LeMaitre Vascular, Inc. (LMAT), reported on Form 4 that on 09/04/2025 he received dividend equivalent rights tied to previously granted equity awards. The Form 4 lists five separate accruals of dividend equivalent rights that arose from restricted stock unit and performance stock unit awards granted on 12/12/2022, 12/8/2023 and 12/6/2024. Each dividend equivalent right is described as the economic equivalent of one share of common stock and vests proportionately with the underlying award. The filing shows fractional share amounts for each accrual and the number of shares beneficially owned following the transactions. The Form 4 was signed by Nathan Ulrich on 09/08/2025.
LeMaitre Vascular insider report: This Form 4, filed for Trent G. Kamke (Senior V.P., Operations), discloses accrual and acquisition of dividend equivalent rights tied to restricted stock unit (RSU) and performance share unit (PSU) awards that vest proportionately. Transactions are dated 09/04/2025. The report lists multiple accruals that convert economically to common shares, with individual tranche amounts shown (examples: 0.3386, 0.6173, 1.2562, 1.6108, 1.9307, 1.9194). No cash consideration is reported and ownership form is direct. The filing documents routine compensation-related accruals rather than open-market purchases or sales.